• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯化羟基氧杂蒽酮作为抗癌剂的合理设计:分子对接、分子动力学模拟、药物代谢动力学/药物毒性预测、一锅法合成及体外评价

Rational Design of Chlorinated Hydroxyxanthone as Anticancer Agent: Molecular Docking, Molecular Dynamic Simulation, ADMET, One-Pot Synthesis, and In Vitro Evaluation.

作者信息

Kurniawan Yehezkiel Steven, Fatmasari Nela, Yudha Ervan, Pranowo Harno Dwi, Sholikhah Eti Nurwening

机构信息

Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

出版信息

Cell Biochem Biophys. 2025 Jun 9. doi: 10.1007/s12013-025-01796-1.

DOI:10.1007/s12013-025-01796-1
PMID:40490674
Abstract

Nowadays, the discovery of active anticancer agents has become urgent research due to the high mortality of cancer patients. Herein, we designed some chlorinated hydroxyxanthones to examine the effect of the presence and position of the chloro group on the inhibitory activity of the PDGFR. The molecular docking reveals that 5-chloro-1-hydroxyxanthone (5Cl) exhibited the strongest binding energy (-7.95 kcal/mol) against PDGFR. The molecular dynamic simulation results demonstrated a high stability of the 5Cl-PDGFR complex as revealed by the average RMSD (0.37 ± 0.15 Å) and RMSF (0.83 ± 0.64 Å), and two maintained hydrogen bonds with Cys673 through hydroxyl and carbonyl groups with an average bond distance of 2.29 ± 0.54 and 2.49 ± 0.64 Å, respectively. Afterward, 5Cl and other chlorinated hydroxyxanthones were synthesized in a one-pot reaction with a 15.1-25.2% yield. From the in vitro experiment, 5Cl exhibited the lowest IC value of 3.065-3.785 µM against breast (MCF-7), cervical (HeLa), and colorectal (WiDr) cancer cells. Furthermore, 5Cl exhibited the highest selectivity index (8.737-10.79), showing that 5Cl is not toxic to the Vero normal cells, which agreed with the ADMET predictions. These findings highlight the potential application of 5Cl as a new anticancer agent that will be investigated further and developed in the future.

摘要

如今,由于癌症患者的高死亡率,发现活性抗癌药物已成为紧迫的研究课题。在此,我们设计了一些氯化羟基氧杂蒽酮,以研究氯原子的存在和位置对血小板衍生生长因子受体(PDGFR)抑制活性的影响。分子对接显示,5-氯-1-羟基氧杂蒽酮(5Cl)对PDGFR表现出最强的结合能(-7.95千卡/摩尔)。分子动力学模拟结果表明,5Cl-PDGFR复合物具有很高的稳定性,平均均方根偏差(RMSD)为(0.37±0.15埃),均方根波动(RMSF)为(0.83±0.64埃),并且通过羟基和羰基与半胱氨酸673保持两个氢键,平均键距分别为2.29±0.54埃和2.49±0.64埃。随后,5Cl和其他氯化羟基氧杂蒽酮通过一锅法反应合成,产率为15.1-25.2%。体外实验表明,5Cl对乳腺癌(MCF-7)、宫颈癌(HeLa)和结直肠癌(WiDr)细胞的最低半数抑制浓度(IC)值为3.065-3.785微摩尔。此外,5Cl表现出最高的选择性指数(8.737-10.79),表明5Cl对非洲绿猴肾(Vero)正常细胞无毒,这与药物代谢和毒性预测结果一致。这些发现突出了5Cl作为一种新型抗癌药物的潜在应用价值,未来将对其进行进一步研究和开发。

相似文献

1
Rational Design of Chlorinated Hydroxyxanthone as Anticancer Agent: Molecular Docking, Molecular Dynamic Simulation, ADMET, One-Pot Synthesis, and In Vitro Evaluation.氯化羟基氧杂蒽酮作为抗癌剂的合理设计:分子对接、分子动力学模拟、药物代谢动力学/药物毒性预测、一锅法合成及体外评价
Cell Biochem Biophys. 2025 Jun 9. doi: 10.1007/s12013-025-01796-1.
2
Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents.羟基黄烷酮类化合物的合成及抗氧化和抗癌活性评价。
Sci Rep. 2022 Jan 27;12(1):1535. doi: 10.1038/s41598-022-05573-5.
3
Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.靶向VEGFR-2酶的新型三唑并[3,4-a]酞嗪衍生物的设计、合成、体外抗癌活性、ADMET特性及分子对接
Anticancer Agents Med Chem. 2018;18(8):1184-1196. doi: 10.2174/1871520618666180412123833.
4
Chemical Characterization, Evaluation, and Molecular Docking Analysis of Antiproliferative Compounds Isolated from the Bark of Miq.从 Miq. 的树皮中分离得到的具有抗增殖活性的化合物的化学特征、评价和分子对接分析
Anticancer Agents Med Chem. 2022;22(20):3416-3437. doi: 10.2174/1871520622666220204123348.
5
Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.吡啶衍生的 VEGFR-2 抑制剂:合理设计、合成、抗癌评估、计算 ADMET 概况和分子对接。
Arch Pharm (Weinheim). 2021 Aug;354(8):e2100085. doi: 10.1002/ardp.202100085. Epub 2021 May 5.
6
Computational and Molecular Docking Studies of New Benzene Sulfonamide Drugs with Anticancer and Antioxidant Effects.具有抗癌和抗氧化作用的新型苯磺酰胺类药物的计算和分子对接研究。
Curr Org Synth. 2023;20(3):339-350. doi: 10.2174/1570179420666221007141937.
7
Novel 5-Fluorouracil analogues versus perfluorophenyl ureas as potent anti-breast cancer agents: Design, robust synthesis, in vitro, molecular docking, pharmacokinetics ADMET analysis and dynamic simulations.新型5-氟尿嘧啶类似物与全氟苯基脲作为强效抗乳腺癌药物的比较:设计、稳健合成、体外研究、分子对接、药代动力学ADMET分析及动力学模拟
Bioorg Chem. 2024 Dec;153:107944. doi: 10.1016/j.bioorg.2024.107944. Epub 2024 Nov 6.
8
Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation.作为潜在抗癌剂的右布洛芬酰胺衍生物:合成、计算机辅助对接、生物评价及分子动力学模拟
Drug Des Devel Ther. 2019 May 14;13:1643-1657. doi: 10.2147/DDDT.S178595. eCollection 2019.
9
Design anticancer potential of Zn(II)isoleucinedithiocarbamate complex on MCF-7 cell lines: synthesis, characterization, molecular docking, molecular dynamic, ADMET, and in-vitro studies.异亮氨酸二硫代氨基甲酸锌(II)配合物对MCF - 7细胞系的抗癌潜力设计:合成、表征、分子对接、分子动力学、ADMET及体外研究
Mol Divers. 2024 Oct;28(5):3199-3214. doi: 10.1007/s11030-023-10747-y. Epub 2023 Oct 27.
10
Investigations of Ni(II)Cysteine-Tyrosine Dithiocarbamate Complex: Synthesis, Characterization, Molecular Docking, Molecular Dynamic, and Anticancer Activity on MCF-7 Breast Cancer Cell Line.镍(II)半胱氨酸-酪氨酸二硫代氨基甲酸盐配合物的研究:合成、表征、分子对接、分子动力学模拟及对 MCF-7 乳腺癌细胞系的抗癌活性。
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1301-1313. doi: 10.31557/APJCP.2024.25.4.1301.

本文引用的文献

1
Design and evaluation of novel triazole derivatives as potential anti-gout inhibitors: a comprehensive molecular modeling study.新型三唑衍生物作为潜在抗痛风抑制剂的设计与评价:一项全面的分子模拟研究
Front Chem. 2025 Mar 6;13:1518777. doi: 10.3389/fchem.2025.1518777. eCollection 2025.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Towards targeting EGFR and COX-2 inhibitors: comprehensive computational studies on the role of chlorine group in novel thienyl-pyrazoline derivative.
针对 EGFR 和 COX-2 抑制剂:新型噻吩基吡唑啉衍生物中氯原子作用的综合计算研究。
J Biomol Struct Dyn. 2024;42(19):9857-9872. doi: 10.1080/07391102.2023.2252915. Epub 2023 Aug 29.
4
Receptor tyrosine kinase inhibitors in cancer.受体酪氨酸激酶抑制剂在癌症中的应用。
Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4.
5
Design and Synthesis of Xanthone Analogues Conjugated with Aza-aromatic Substituents as Promising G-Quadruplex Stabilizing Ligands and their Selective Cancer Cell Cytotoxic Action.具有氮杂芳基取代基的蒽酮类似物的设计与合成作为有前途的 G-四链体稳定配体及其对癌细胞的选择性细胞毒性作用。
Chembiochem. 2023 Feb 14;24(4):e202200609. doi: 10.1002/cbic.202200609. Epub 2023 Jan 17.
6
Xanthones and anthraquinones from the soil fungus sp. DWS10-P-6.土壤真菌sp. DWS10-P-6中的呫吨酮和蒽醌
RSC Adv. 2021 Jan 14;11(5):3162-3167. doi: 10.1039/d0ra08141h. eCollection 2021 Jan 11.
7
Natural product drug discovery in the artificial intelligence era.人工智能时代的天然产物药物发现
Chem Sci. 2021 Dec 13;13(6):1526-1546. doi: 10.1039/d1sc04471k. eCollection 2022 Feb 9.
8
Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents.羟基黄烷酮类化合物的合成及抗氧化和抗癌活性评价。
Sci Rep. 2022 Jan 27;12(1):1535. doi: 10.1038/s41598-022-05573-5.
9
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review.靶向血小板衍生生长因子/血小板衍生生长因子受体信号通路用于癌症治疗:综述
Int J Biol Macromol. 2022 Mar 31;202:539-557. doi: 10.1016/j.ijbiomac.2022.01.113. Epub 2022 Jan 21.
10
The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis.MTT assay:在批量和单细胞分析中的应用、局限性、陷阱和解释。
Int J Mol Sci. 2021 Nov 26;22(23):12827. doi: 10.3390/ijms222312827.